Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Equities researchers at Oppenheimer reduced their FY2020 earnings estimates for shares of Syros Pharmaceuticals in a research report issued on Monday, according to Zacks Investment Research. Oppenheimer analyst L. Cann now expects that the company will post earnings per share of ($0.88) for the year, down from their previous estimate of ($0.19). Oppenheimer currently has a “Buy” rating and a $28.00 target price on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ FY2021 earnings at $1.07 EPS.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. HC Wainwright restated a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Roth Capital began coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective for the company. Finally, Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Syros Pharmaceuticals has an average rating of “Buy” and an average price target of $22.36.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.53).
A number of institutional investors have recently made changes to their positions in SYRS. ARK Investment Management LLC grew its holdings in Syros Pharmaceuticals by 519.7% in the 4th quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock worth $8,122,000 after acquiring an additional 700,058 shares during the last quarter. FMR LLC grew its holdings in Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after acquiring an additional 418,061 shares during the last quarter. Vanguard Group Inc. grew its holdings in Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after acquiring an additional 250,507 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in shares of Syros Pharmaceuticals in the 3rd quarter worth about $1,766,000. Finally, State Street Corp lifted its position in shares of Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock worth $2,728,000 after purchasing an additional 108,250 shares during the period. 48.41% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Jeremy P. Springhorn bought 15,000 shares of Syros Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, with a total value of $136,200.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Srinivas Akkaraju purchased 109,774 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, for a total transaction of $991,259.22. The disclosure for this purchase can be found here. In the last three months, insiders purchased 334,198 shares of company stock worth $3,127,458. 33.60% of the stock is currently owned by insiders.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.